vs

Side-by-side financial comparison of MALIBU BOATS, INC. (MBUU) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.

Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $188.6M, roughly 1.0× MALIBU BOATS, INC.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -5.8%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $8.2M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs -3.7%).

Malibu Boats is an American manufacturer of recreational boats, founded in Merced, California in 1982, and currently headquartered in Loudon, Tennessee with additional production facilities in New South Wales, Australia. Malibu is "the world's largest manufacturer of watersports towboats", used both recreationally and in water skiing and wakeboarding events.

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.

MBUU vs PCRX — Head-to-Head

Bigger by revenue
PCRX
PCRX
1.0× larger
PCRX
$196.9M
$188.6M
MBUU
Growing faster (revenue YoY)
PCRX
PCRX
+11.0% gap
PCRX
5.1%
-5.8%
MBUU
More free cash flow
PCRX
PCRX
$35.2M more FCF
PCRX
$43.5M
$8.2M
MBUU
Faster 2-yr revenue CAGR
PCRX
PCRX
Annualised
PCRX
8.5%
-3.7%
MBUU

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
MBUU
MBUU
PCRX
PCRX
Revenue
$188.6M
$196.9M
Net Profit
$-2.5M
Gross Margin
13.3%
79.5%
Operating Margin
-1.9%
1.2%
Net Margin
-1.3%
Revenue YoY
-5.8%
5.1%
Net Profit YoY
-204.2%
EPS (diluted)
$-0.13
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MBUU
MBUU
PCRX
PCRX
Q4 25
$188.6M
$196.9M
Q3 25
$194.7M
$179.5M
Q2 25
$207.0M
$181.1M
Q1 25
$228.7M
$168.9M
Q4 24
$200.3M
$187.3M
Q3 24
$171.6M
$168.6M
Q2 24
$158.7M
$178.0M
Q1 24
$203.4M
$167.1M
Net Profit
MBUU
MBUU
PCRX
PCRX
Q4 25
$-2.5M
Q3 25
$-702.0K
$5.4M
Q2 25
$4.7M
$-4.8M
Q1 25
$12.9M
$4.8M
Q4 24
$2.4M
Q3 24
$-5.0M
$-143.5M
Q2 24
$-19.2M
$18.9M
Q1 24
$-66.8M
$9.0M
Gross Margin
MBUU
MBUU
PCRX
PCRX
Q4 25
13.3%
79.5%
Q3 25
14.3%
80.9%
Q2 25
15.8%
77.4%
Q1 25
20.0%
79.7%
Q4 24
18.7%
78.7%
Q3 24
16.4%
76.9%
Q2 24
7.9%
75.1%
Q1 24
19.8%
71.6%
Operating Margin
MBUU
MBUU
PCRX
PCRX
Q4 25
-1.9%
1.2%
Q3 25
-0.4%
3.5%
Q2 25
3.3%
4.7%
Q1 25
7.6%
1.2%
Q4 24
1.6%
13.2%
Q3 24
-3.3%
-82.8%
Q2 24
-15.4%
15.9%
Q1 24
-36.8%
7.9%
Net Margin
MBUU
MBUU
PCRX
PCRX
Q4 25
-1.3%
Q3 25
-0.4%
3.0%
Q2 25
2.3%
-2.7%
Q1 25
5.6%
2.8%
Q4 24
1.2%
Q3 24
-2.9%
-85.1%
Q2 24
-12.1%
10.6%
Q1 24
-32.9%
5.4%
EPS (diluted)
MBUU
MBUU
PCRX
PCRX
Q4 25
$-0.13
$0.05
Q3 25
$-0.04
$0.12
Q2 25
$0.23
$-0.11
Q1 25
$0.66
$0.10
Q4 24
$0.12
$0.38
Q3 24
$-0.25
$-3.11
Q2 24
$-0.93
$0.39
Q1 24
$-3.28
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MBUU
MBUU
PCRX
PCRX
Cash + ST InvestmentsLiquidity on hand
$28.2M
$238.4M
Total DebtLower is stronger
$20.0M
$372.2M
Stockholders' EquityBook value
$495.0M
$693.1M
Total Assets
$715.7M
$1.3B
Debt / EquityLower = less leverage
0.04×
0.54×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MBUU
MBUU
PCRX
PCRX
Q4 25
$28.2M
$238.4M
Q3 25
$44.1M
$246.3M
Q2 25
$37.0M
$445.9M
Q1 25
$38.7M
$493.6M
Q4 24
$35.1M
$484.6M
Q3 24
$27.7M
$453.8M
Q2 24
$26.9M
$404.2M
Q1 24
$47.1M
$325.9M
Total Debt
MBUU
MBUU
PCRX
PCRX
Q4 25
$20.0M
$372.2M
Q3 25
$23.0M
$376.7M
Q2 25
$18.0M
$580.5M
Q1 25
$28.0M
$583.4M
Q4 24
$23.0M
$585.3M
Q3 24
$28.0M
Q2 24
$0
Q1 24
$15.0M
Stockholders' Equity
MBUU
MBUU
PCRX
PCRX
Q4 25
$495.0M
$693.1M
Q3 25
$516.4M
$727.2M
Q2 25
$515.5M
$757.8M
Q1 25
$513.0M
$798.5M
Q4 24
$509.8M
$778.3M
Q3 24
$517.7M
$749.6M
Q2 24
$530.0M
$879.3M
Q1 24
$557.2M
$892.2M
Total Assets
MBUU
MBUU
PCRX
PCRX
Q4 25
$715.7M
$1.3B
Q3 25
$755.6M
$1.3B
Q2 25
$734.6M
$1.5B
Q1 25
$758.8M
$1.6B
Q4 24
$738.7M
$1.6B
Q3 24
$759.1M
$1.5B
Q2 24
$739.6M
$1.6B
Q1 24
$797.6M
$1.6B
Debt / Equity
MBUU
MBUU
PCRX
PCRX
Q4 25
0.04×
0.54×
Q3 25
0.04×
0.52×
Q2 25
0.03×
0.77×
Q1 25
0.05×
0.73×
Q4 24
0.05×
0.75×
Q3 24
0.05×
Q2 24
0.00×
Q1 24
0.03×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MBUU
MBUU
PCRX
PCRX
Operating Cash FlowLast quarter
$12.6M
$43.7M
Free Cash FlowOCF − Capex
$8.2M
$43.5M
FCF MarginFCF / Revenue
4.4%
22.1%
Capex IntensityCapex / Revenue
2.3%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$33.3M
$136.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MBUU
MBUU
PCRX
PCRX
Q4 25
$12.6M
$43.7M
Q3 25
$6.5M
$60.8M
Q2 25
$21.0M
$12.0M
Q1 25
$15.5M
$35.5M
Q4 24
$28.4M
$33.1M
Q3 24
$-8.4M
$53.9M
Q2 24
$16.3M
$53.2M
Q1 24
$23.5M
$49.1M
Free Cash Flow
MBUU
MBUU
PCRX
PCRX
Q4 25
$8.2M
$43.5M
Q3 25
$2.2M
$57.0M
Q2 25
$14.1M
$9.3M
Q1 25
$8.8M
$26.9M
Q4 24
$22.8M
$31.0M
Q3 24
$-17.0M
$49.8M
Q2 24
$4.5M
$51.6M
Q1 24
$11.5M
$46.3M
FCF Margin
MBUU
MBUU
PCRX
PCRX
Q4 25
4.4%
22.1%
Q3 25
1.1%
31.7%
Q2 25
6.8%
5.1%
Q1 25
3.8%
15.9%
Q4 24
11.4%
16.6%
Q3 24
-9.9%
29.6%
Q2 24
2.8%
29.0%
Q1 24
5.7%
27.7%
Capex Intensity
MBUU
MBUU
PCRX
PCRX
Q4 25
2.3%
0.1%
Q3 25
2.2%
2.2%
Q2 25
3.4%
1.5%
Q1 25
2.9%
5.1%
Q4 24
2.8%
1.1%
Q3 24
5.0%
2.4%
Q2 24
7.5%
0.9%
Q1 24
5.9%
1.7%
Cash Conversion
MBUU
MBUU
PCRX
PCRX
Q4 25
Q3 25
11.20×
Q2 25
4.50×
Q1 25
1.20×
7.37×
Q4 24
12.02×
Q3 24
Q2 24
2.82×
Q1 24
5.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MBUU
MBUU

Boatand Trailer Sales$68.1M36%
Saltwater Fishing$65.3M35%
Cobalt$52.6M28%
Part And Other Sales$2.6M1%

PCRX
PCRX

EXPAREL$155.8M79%
ZILRETTA$33.0M17%
Iovera$7.0M4%

Related Comparisons